Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A randomized, controlled phase II clinical trial of Fruquintinib combined with Raltitrexed
versus Fruquintinib monotherapy in patients with advanced colorectal cancer who had failed
second-line or above standard chemotherapy